Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Depreciation and Depletion (2022 - 2025)

Historic Depreciation and Depletion for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $120000.0.

  • Axsome Therapeutics' Depreciation and Depletion fell 839.69% to $120000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $518000.0, marking a year-over-year decrease of 335.82%. This contributed to the annual value of $532000.0 for FY2024, which is 1590.41% up from last year.
  • Axsome Therapeutics' Depreciation and Depletion amounted to $120000.0 in Q3 2025, which was down 839.69% from $120000.0 recorded in Q2 2025.
  • Axsome Therapeutics' Depreciation and Depletion's 5-year high stood at $149000.0 during Q1 2025, with a 5-year trough of $37000.0 in Q1 2022.
  • Moreover, its 4-year median value for Depreciation and Depletion was $120000.0 (2025), whereas its average is $109533.3.
  • In the last 5 years, Axsome Therapeutics' Depreciation and Depletion soared by 14324.32% in 2023 and then crashed by 1428.57% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Depreciation and Depletion (Quarter) stood at $85000.0 in 2022, then soared by 56.47% to $133000.0 in 2023, then decreased by 3.01% to $129000.0 in 2024, then dropped by 6.98% to $120000.0 in 2025.
  • Its last three reported values are $120000.0 in Q3 2025, $120000.0 for Q2 2025, and $149000.0 during Q1 2025.